Idiopathic Pulmonary Fibrosis

New England Journal of Medicine

Volumn 378, Issue 19, 2018, Pages 1811-1823

  Lederer, David J ^a   Martinez, Fernando J ^b  

^a Department of Medicine   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; NINTEDANIB; PIRFENIDONE; ENZYME INHIBITOR; INDOLE DERIVATIVE; PYRIDONE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA;

ANOREXIA; CELL ADHESION; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DEATH; DIAGNOSTIC ERROR; DIARRHEA; DRUG DOSE REDUCTION; DYSPNEA; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GENE; GENE MUTATION; HOME OXYGEN THERAPY; HOSPITAL ADMISSION; HUMAN; LUNG ALVEOLUS EPITHELIUM CELL; LUNG TRANSPLANTATION; MECHANOTRANSDUCTION; MORTALITY RATE; NAUSEA; PARN GENE; PREVALENCE; PRIORITY JOURNAL; PULMONARY REHABILITATION; REVIEW; RISK FACTOR; RTEL1 GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TELOMERE LENGTH; TERT GENE; UNITED STATES; VOMITING; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; LUNG; OXYGEN THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; X-RAY COMPUTED TOMOGRAPHY;

DIAGNOSIS, DIFFERENTIAL; DYSPNEA; ENZYME INHIBITORS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; LUNG; OXYGEN INHALATION THERAPY; PROGNOSIS; PYRIDONES; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TRANSFORMING GROWTH FACTOR BETA;

EID: 85046961000     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1705751     Document Type: Review

References (100)

1. Rosas IO, Dellaripa PF, Lederer DJ, Khanna D, Young LR, Martinez FJ. Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc 2014;11: Suppl 3:S169-S177.
2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.
3. Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 2015;46:795-806.
4. Esposito DB, Lanes S, Donneyong M, et al. Idiopathic pulmonary fibrosis in United States automated claims: incidence, prevalence, and algorithm validation. Am J Respir Crit Care Med 2015;192:1200-7.
5. Raghu G, Chen SY, Hou Q, Yeh WS, Collard HR. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old. Eur Respir J 2016;48:179-86.
6. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014;2:566-72.
7. Hutchinson JP, McKeever TM, Fogarty AW, Navaratnam V, Hubbard RB. Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. Ann Am Thorac Soc 2014;11:1176-85.
8. Navaratnam V, Fogarty AW, Glendening R, McKeever T, Hubbard RB. The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010. Chest 2013;143:1078-84.
9. Hewson T, McKeever TM, Gibson JE, Navaratnam V, Hubbard RB, Hutchinson JP. Timing of onset of symptoms in people with idiopathic pulmonary fibrosis. Thorax 2017 October 11 (Epub ahead of print).
10. The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366:1968-77.
11. Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 2017;72:340-6.
12. Albera C, Costabel U, Fagan EA, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J 2016; 48:843-51.
13. Cottin V, Hansell DM, Sverzellati N, et al. Effect of emphysema extent on serial lung function in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2017;196:1162-71.
14. Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model. Am J Respir Crit Care Med 2014;189:1161-72.
15. Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 2008;105:13051-6.
16. Armanios MY, Chen JJ-L, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007;356:1317-26.
17. Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 2007;104:7552-7.
18. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013;45:613-20.
19. Allen RJ, Porte J, Braybrooke R, et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir Med 2017;5:869-80.
20. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011;364:1503-12.
21. Roy MG, Livraghi-Butrico A, Fletcher AA, et al. Muc5b is required for airway defence. Nature 2014;505:412-6.
22. Nakano Y, Yang IV, Walts AD, et al. MUC5B promoter variant rs35705950 affects MUC5B expression in the distal airways in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016;193:464-6.
23. Molyneaux PL, Willis-Owen SAG, Cox MJ, et al. Host-microbial interactions in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2017;195:1640-50.
24. Morris A, Gibson K, Collman RG. The lung microbiome in idiopathic pulmonary fibrosis: what does it mean and what should we do about it? Am J Respir Crit Care Med 2014;190:850-2.
25. Misharin AV, Morales-Nebreda L, Reyf-man PA, et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. J Exp Med 2017;214:2387-404.
26. Kitsios GD, Rojas M, Kass DJ, et al. Microbiome in lung explants of idiopathic pulmonary fibrosis: a case-control study in patients with end-stage fibrosis. Thorax 2017 August 11 (Epub ahead of print).
27. Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med 2014;2:548-56.
28. Molyneaux PL, Cox MJ, Willis-Owen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014;190:906-13.
29. Huang Y, Ma SF, Espindola MS, et al. Microbes are associated with host innate immune response in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2017;196:208-19.
30. Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013;1:309-17.
31. Philp CJ, Siebeke I, Clements D, et al. ECM crosslinking enhances fibroblast growth and protects against matrix pro-teolysis in lung fibrosis. Am J Respir Cell Mol Biol 2017 October 20 (Epub ahead of print).
32. Baumgartner KB, Samet JM, Coultas DB, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Am J Epidemiol 2000;152:307-15.
33. Tobin RW, Pope CE II, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;158: 1804-8.
34. Kim JS, Podolanczuk AJ, Borker P, et al. Obstructive sleep apnea and subclinical interstitial lung disease in the Multi-Ethnic Study of Atherosclerosis (MESA). Ann Am Thorac Soc 2017;14:1786-95.
35. Sack C, Vedal S, Sheppard L, et al. Air pollution and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA) air-lung study. Eur Respir J 2017;50(6):1700559.
36. Tang Y-W, Johnson JE, Browning PJ, et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol 2003; 41:2633-40.
37. Podolanczuk AJ, Oelsner EC, Barr RG, et al. High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study. Eur Respir J 2016; 48:1442-52.
38. Podolanczuk AJ, Oelsner EC, Barr RG, et al. High-attenuation areas on chest computed tomography and clinical respiratory outcomes in community-dwelling adults. Am J Respir Crit Care Med 2017; 196:1434-42.
39. Putman RK, Hatabu H, Araki T, et al. Association between interstitial lung abnormalities and all-cause mortality. JAMA 2016;315:672-81.
40. Hunninghake GM, Hatabu H, Okajima Y, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med 2013;368:2192-200.
41. Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society white paper. Lancet Respir Med 2018;6: 138-53.
42. Brownell R, Moua T, Henry TS, et al. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Thorax 2017; 72:424-9.
43. Salisbury ML, Xia M, Murray S, et al. Predictors of idiopathic pulmonary fibrosis in absence of radiologic honeycombing: a cross sectional analysis in ILD patients undergoing lung tissue sampling. Respir Med 2016;118:88-95.
44. Han Q, Luo Q, Xie JX, et al. Diagnostic yield and postoperative mortality associated with surgical lung biopsy for evaluation of interstitial lung diseases: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 2015;149(5): 1394-401.e1.
45. Johannson KA, Marcoux VS, Ronksley PE, Ryerson CJ. Diagnostic yield and complications of transbronchial lung cryobiopsy for interstitial lung disease: a systematic review and metaanalysis. Ann Am Thorac Soc 2016;13:1828-38.
46. Tomassetti S, Wells AU, Costabel U, et al. Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016;193:745-52.
47. DiBardino DM, Haas AR, Lanfranco AR, Litzky LA, Sterman D, Bessich JL. High complication rate after introduction of transbronchial cryobiopsy into clinical practice at an academic medical center. Ann Am Thorac Soc 2017;14:851-7.
48. Patel NM, Borczuk AC, Lederer DJ. Cryobiopsy in the diagnosis of interstitial lung disease: a step forward or back? Am J Respir Crit Care Med 2016;193:707-9.
49. Walsh SLF, Maher TM, Kolb M, et al. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. Eur Respir J 2017;50(2):1700936.
50. Flaherty KR, King TE Jr, Raghu G, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 2004;170:904-10.
51. Walsh SLF, Wells AU, Desai SR, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med 2016;4: 557-65.
52. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008;5(4):e93.
53. White ES, Xia M, Murray S, et al. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2016; 194:1242-51.
54. Yang IV, Luna LG, Cotter J, et al. The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis. PLoS One 2012; 7(6):e37708.
55. Kim SY, Diggans J, Pankratz D, et al. Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Lancet Respir Med 2015; 3:473-82.
56. Pankratz DG, Choi Y, Imtiaz U, et al. Usual interstitial pneumonia can be detected in transbronchial biopsies using machine learning. Ann Am Thorac Soc 2017; 14:1646-54.
57. Dowman LM, McDonald CF, Bozinov-ski S, et al. Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia. Respirology 2017;22:957-64.
58. Dowman LM, McDonald CF, Hill CJ, et al. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Thorax 2017;72: 610-9.
59. Valapour M, Lehr CJ, Skeans MA, et al. OPTN/SRTR 2016 annual data report: lung. Am J Transplant 2018;18:Suppl 1:363-433.
60. Singer JP, Katz PP, Soong A, et al. Effect of lung transplantation on health-related quality of life in the era of the Lung Allocation Score: a U.S. prospective cohort study. Am J Transplant 2017;17:1334-45.
61. Titman A, Rogers CA, Bonser RS, Banner NR, Sharples LD. Disease-specific survival benefit of lung transplantation in adults: a national cohort study. Am J Transplant 2009;9:1640-9.
62. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014 — an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015;34:1-15.
63. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;192(2):e3-e19.
64. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82.
65. King TE Jr, Bradford WZ, Castro-Ber-nardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92.
66. Ley B, Swigris J, Day BM, et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2017;196:756-61.
67. Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 2016;193:178-85.
68. Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med 2017;5:33-41.
69. Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials. Respir Med 2016;113:74-9.
70. Kolb M, Bonella F, Wollin L. Therapeutic targets in idiopathic pulmonary fibrosis. Respir Med 2017;131:49-57.
71. Canestaro WJ, Forrester SH, Raghu G, Ho L, Devine BE. Drug treatment of idiopathic pulmonary fibrosis: systematic review and network meta-analysis. Chest 2016;149:756-66.
72. Rochwerg B, Neupane B, Zhang Y, et al. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med 2016;14:18.
73. Raghu G, Selman M. Nintedanib and pirfenidone: new antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med 2015;191:252-4.
74. Vancheri C, Kreuter M, Richeldi L, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: results of the INJOURNEY Trial. Am J Respir Crit Care Med 2018;197:356-63.
75. The Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014;370: 2093-101.
76. Oldham JM, Ma SF, Martinez FJ, et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015;192:1475-82.
77. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009;374:222-8.
78. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013;158:641-9.
79. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;186: 88-95.
80. Marks PW, Witten CM, Califf RM. Clarifying stem-cell therapy’s benefits and risks. N Engl J Med 2017;376:1007-9.
81. Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013; 1:369-76.
82. Lee JS, Ryu JH, Elicker BM, et al. Gas-troesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:1390-4.
83. Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983;2:267-71.
84. Kreuter M, Wuyts W, Renzoni E, et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 2016;4:381-9.
85. Gorina E, Richeldi L, Raghu G, et al. PRAISE, a randomized, placebo-controlled, double-blind phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients. Eur Respir J 2017;50:Suppl 61:OA3400. abstract.
86. Parker J, Sawtell R, Gagnon L, et al. PBI-4050 is safe and well tolerated and shows evidence of benefit in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2017;195:A7606. abstract.
87. Hirani N, MacKinnon A, Nicol L, et al. TD139, a novel inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF): results from the first in IPF patients study. Am J Respir Crit Care Med 2017;195:A7560. abstract.
88. van den Blink B, Dillingh MR, Ginns LC, et al. Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. Eur Respir J 2016; 47:889-97.
89. Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012; 157:398-406.
90. van Manen MJG, Birring SS, Vancheri C, et al. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur Respir J 2017;50(4):1701157.
91. Abdulqawi R, Dockry R, Holt K, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2015;385:1198-205.
92. Birring SS, Wijsenbeek MS, Agrawal S, et al. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. Lancet Respir Med 2017;5:806-15.
93. Lindell KO, Liang Z, Hoffman LA, et al. Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. Chest 2015;147:423-9.
94. Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis: an International Working Group report. Am J Respir Crit Care Med 2016;194:265-75.
95. Dalleywater W, Powell HA, Fogarty AW, Hubbard RB, Navaratnam V. Venous thromboembolism in people with idiopathic pulmonary fibrosis: a population-based study. Eur Respir J 2014;44:1714-5.
96. Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 2007;101:2534-40.
97. Raghu G, Amatto VC, Behr J, Stowas-ser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 2015;46:1113-30.
98. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology 2017;284:228-43.
99. Moyer VA, U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;160: 330-8.
100. Wiener RS, Ouellette DR, Diamond E, et al. An official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicine. Chest 2014;145:1383-91.